RetaMaps

David Dreyfuss, MD

David Dreyfuss, MD · 9721 165th Street · Orland Park, IL 60467

4.5· 16 Google reviews

Listing updated October 2, 2026

Retatrutide outlook for this practice

No current plans confirmed — RetaMaps has not yet confirmed this practice's intentions regarding retatrutide. Inclusion on RetaMaps does not mean the provider offers or will offer retatrutide.

Care described on the practice's website

  • Medically supervised weight loss

About this practice

David Dreyfuss, MD, is a plastic surgery practice in Orland Park, Illinois, serving the greater Chicago area. Its website says Dr. Dreyfuss is a board-certified plastic surgeon, certified by the American Board of Plastic Surgery, and lists procedures such as breast augmentation, liposuction, eyelid surgery and laser skin resurfacing, along with laser hair removal. On Google it has a 4.5-star rating across 16 reviews dating back to 2018, with 2 posted in the past year. Reviewers most often mention the staff, and 3 each mention results and the doctor's knowledge.

Services & access

Advertises semaglutide todayNot listed
Advertises tirzepatide todayNot listed
Telehealth visitsNot listed
Cash pay accepted—
Accepts insurance — per practice websiteYes
Accepting new patients — per practice websiteYes

"Not listed" means we didn't find this stated on the practice's public pages — it doesn't mean no. — means unknown. Medication rows describe currently FDA-approved GLP-1 medications the practice advertises today, not retatrutide. Confirm details directly with the practice.

Review activity

★ 4.5
Google rating · 16 reviews
2
reviews in the past year (avg ★ 5.0)

Counts computed by RetaMaps from public Google reviews; most recent review 2026-09-29. Read the reviews themselves on the practice's Google listing.

What patients say

Rated ★4.5 across 16 Google reviews. Of the 16 reviews we analyzed, 14 (88%) are positive (4–5★) and 2 (13%) are negative (1–2★).

What patients like

  • Friendly, helpful staff6 reviews
  • Weight-loss results3 reviews
  • Knowledgeable, professional providers3 reviews
  • Feeling listened to3 reviews

Common complaints

Very few complaints — only 2 negative reviews, with no recurring theme.

5★
14
4★
0
3★
0
2★
0
1★
2

Most recent Google reviews

Kelly G.★★★★★2026-09-29

Dr Dreyfuss and the entire staff are very professional and extremely knowledgeable. The experience he has shows in his work.

Michele E.★★★★★2026-09-01

I’m 54 and have gone to him since was 35 for pretty much some of everything. He’s excellent at what he does. Highly recommend 🤞🏽

Ariel P.★★★★★2024-08-20

Dr. Dreyfuss is an amazing surgeon who listened and made me feel comfortable with the decision I was making. Highly recommend!

Flora B.★★★★★2024-07-17

Dr. Dreyfuss is extremely confident and is superb in what he does. Outstanding bedside manners.

Penni M.★★★★★2024-02-22

Dr. Dreyfuss is an amazing surgeon with equally amazing results! I recommend him to literally everyone that talks about wanting plastic surgery. He takes the time to make sure you understand all of your options and really makes you feel comfortable, as well as the ladies that work in the office. Thanks doctor!!

Analysis by RetaMaps of reviews on this practice's public Google Business listing; review themes are detected automatically and reviews reflect their authors' opinions. See all reviews on Google.

Clinicians

  • David Dreyfuss, MD

Nearby providers in Orland Park

Retatrutide status
Phase 3 complete · Not FDA-approvedUpdated October 2, 2026

Retatrutide is Eli Lilly's investigational once-weekly triple agonist (GIP, GLP-1 and glucagon receptors). Five Phase 3 trials have reported positive results, and Lilly plans to submit it to the FDA in Q1 2027. It is not FDA-approved, has no brand name or price, and cannot be prescribed outside clinical trials or Lilly's physician-requested expanded access program. Products sold online as "research" or compounded retatrutide are not legitimate retatrutide.

Development
Phase 3 complete
FDA status
Submission planned — Q1 2027 (Lilly guidance)
Availability
Not commercially available
Access routes
Clinical trials, or Lilly's expanded access program (physician must apply)

Next milestone: TRIUMPH-5 head-to-head vs tirzepatide results (Expected ~Dec 2026)

Sources: Lilly — What to know about retatrutide · Lilly — TRIUMPH-2/TRIUMPH-3 results · BioPharma Dive — FDA submission plans · STAT — Lilly expanded access (Aug 3, 2026) · FDA — Concerns with unapproved GLP-1 drugs